Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:1677

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles

(Circulation. 2005;112:1677.)
© 2005 American Heart Association, Inc.

Issue Highlights


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    LEVELS OF HEMATOPOIESIS INHIBITOR N-ACETYL-SERYL-ASPARTYL-LYSYL-PROLINE PARTIALLY EXPLAIN THE OCCURRENCE OF ANEMIA IN HEART FAILURE, by van der Meer et al.
 
There is evidence that inhibition of the renin-angiotensin system is associated with the development of anemia in patients. Of 98 patients with heart failure who were treated with angiotensin-converting enzyme (ACE) inhibitors, 10 had unexplained anemia. They were compared to 10 without anemia. The anemic patients had lower serum ACE activity; their serum inhibited proliferation of bone marrow–derived hematopoietic progenitor cells from healthy donors; and their levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), which is degraded by ACE, were higher. These preliminary findings led the authors to propose that ACE inhibitors might contribute to anemia by increasing the levels of Ac-SDKP. See p 1743.


*    SAFETY AND FEASIBILITY OF AUTOLOGOUS MYOBLAST TRANSPLANTATION IN PATIENTS WITH ISCHEMIC CARDIOMYOPATHY: FOUR-YEAR FOLLOW-UP, by Dib et al.
 
Although there is increasing experience with myoblast transplantation by direct intramyocardial injection in patients, little is known about the long-term viability and function of the injected cells. Dib et al provide follow-up for a mean of 27 months in 24 patients who received autologous myoblast injections at the time of coronary bypass surgery and at a mean of 9 months in 6 additional patients who received injections at the time of left ventricular assist device placement. There was PET evidence of increased glucose uptake and echocardiographic evidence of improved cardiac function. There was also histological evidence of myoblast survival in 4 of 6 patients studied 5 days to 6 months after injection. Together, these observations support the feasibility of myoblast transplantation and suggest that injected cells are viable for up to several months. See p 1748.


*    ARTERIAL DISTENSIBILITY IN ADOLESCENTS: THE INFLUENCE OF ADIPOSITY, THE METABOLIC SYNDROME, AND CLASSIC RISK FACTORS, by Whincup et al.
 
Atherosclerosis develops from childhood, but the determinants of this . . . [Full Text of this Article]


Related Articles:

Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure
Peter van der Meer, Erik Lipsic, B. Daan Westenbrink, Ruud M.A. van de Wal, Regien G. Schoemaker, Edo Vellenga, Dirk J. van Veldhuisen, Adriaan A. Voors, and Wiek H. van Gilst
Circulation 2005 112: 1743-1747. [Abstract] [Full Text]

Safety and Feasibility of Autologous Myoblast Transplantation in Patients With Ischemic Cardiomyopathy: Four-Year Follow-Up
Nabil Dib, Robert E. Michler, Francis D. Pagani, Susan Wright, Dean J. Kereiakes, Rose Lengerich, Philip Binkley, Diane Buchele, Inder Anand, Cory Swingen, Marcelo F. Di Carli, James D. Thomas, Wael A. Jaber, Shaun R. Opie, Ann Campbell, Patrick McCarthy, Michael Yeager, Vasken Dilsizian, Bartley P. Griffith, Ronald Korn, Steven K. Kreuger, Marwan Ghazoul, W. Robb MacLellan, Gregg Fonarow, Howard J. Eisen, Jonathan Dinsmore, and Edward Diethrich
Circulation 2005 112: 1748-1755. [Abstract] [Full Text]

Arterial Distensibility in Adolescents: The Influence of Adiposity, the Metabolic Syndrome, and Classic Risk Factors
P.H. Whincup, J.A. Gilg, A.E. Donald, M. Katterhorn, C. Oliver, D.G. Cook, and J.E. Deanfield
Circulation 2005 112: 1789-1797. [Abstract] [Full Text]

Extracardiac Unruptured Sinus of Valsalva, Coronary, and Intracranial Aneurysms
Ghassan Sleilaty, Issam El Rassi, Fadi Haddad, and Victor A. Jebara
Circulation 2005 112: e146-e147. [Extract] [Full Text]

Encasement of the Heart by Calcific Constrictive Pericardium
T. Georgie, M. Vijayakumar, K.K. Mahesh, and K.K. Haridas
Circulation 2005 112: e148-e150. [Extract] [Full Text]

Endovascular Treatment of a Giant Aortic Arch Aneurysm With a Triple-Branched Stent Graft
Naritatsu Saito, Takeshi Kimura, Masanao Toma, Toru Kita, Moriaki Inoko, Ryuji Nohara, and Kanji Inoue
Circulation 2005 112: e151-e152. [Extract] [Full Text]

Letter Regarding Article by Luo et al, "Adenovirus-Mediated Expression of ß-Adrenergic Receptor Kinase C-Terminus Reduces Intimal Hyperplasia and Luminal Stenosis of Arteriovenous Polytetrafluoroethylene Grafts in Pigs" Response
Joris I. Rotmans, Erik S.G. Stroes, Gerard Pasterkamp, Zhengyu Luo, Geoffrey Y. Akita, Taro Date, Christopher Treleaven, Karen A. Vincent, Denise Woodcock, Seng H. Cheng, Richard J. Gregory, and Canwen Jiang
Circulation 2005 112: e153. [Extract] [Full Text]